Q-omics provides the consensus-scored MARCHF7 profile across patient tissues and cancer cell-line models. MARCHF7 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MARCHF7 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, MARCHF7 RNA expression shows 21,550 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where MARCHF7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MARCHF7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MARCHF7 survival associations across molecular data types. MARCHF7 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MARCHF7 RNA expression–survival associations across cancer types. High MARCHF7 expression shows unfavorable associations in ACC, LIHC, KIRP, UVM and LGG, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MARCHF7 RNA expression.
This table summarizes MARCHF7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MARCHF7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MARCHF7 shows lower tumor expression in KICH, THCA and UCEC and higher tumor expression in HNSC, LIHC and CHOL. The HNSC box plot shows higher MARCHF7 RNA expression in tumor versus normal tissue (log2 FC = +0.423, t-test p < 0.001).
This table shows molecular features associated with MARCHF7 in patient tissues and cancer cell lines. In patient samples, MARCHF7 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MARCHF7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
